From the report:The Directors are of the opinion the Group is a...

From the report:

The Directors are of the opinion the Group is a going concernbased on the cashflow projections prepared for twelve monthsbeyond the date of approval of these financial statements,which incorporate the following factors:

— Continued revenue growth of the Estradiol product;
— Launching one product which has received FDA approval;
— Obtaining FDA approval and launching further products,which are currently undergoing the FDA review process;and,
— The continued eligibility of product developmentexpenditure for the research and development taxincentive rebate.


Additionally, the Directors continue to monitor expenditure against budget and are exploring other options should the cashflows be materially different to those forecast. In the event of a product launch which may be delayed, the Company could implement cash management strategies which could include:
— Deferral of current year project development expenditure;
— Management of operating expenses; or
— Monetisation of assets, such as actioning advance receipt
of research and development tax incentive rebate or other revenue streams. On this basis no adjustments have been made to the financial report relating to the recoverability and classification of the carrying amount of assets or the amount and classification of liabilities that might be necessary should the Group not continue as a going concern. Accordingly, the financial report has been prepared on a going concern basis. Should the Group be unsuccessful with the initiatives detailed above then, there is a material uncertainty as to whether the Group may be able to continue as a going concern and may therefore be required to realise assets and extinguish liabilities other than in the ordinary course of business with the amount realised being different from those shown in the financial statements.